NDA Resubmission, Accelerated Assessment of Marketing Application, and Esteemed Recognition - Analyst Notes on McKesson, AbbVie, Lilly, Zoetis and Salix

NEW YORK, June 20, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding McKesson Corporation (NYSE: MCK), AbbVie Inc. (NYSE: ABBV), Eli Lilly and Company (NYSE: LLY), Zoetis Inc. (NYSE: ZTS) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3930-100free.

McKesson Corporation Analyst Notes
On June 17, 2014, McKesson Corporation's (McKesson) stock increased 1.16% to close trading at $184.66 per share. Over the past month of trading, McKesson's stock gained 3.62% while the Dow Jones Industrial Average also increased by 1.92% over the same trading period. The full analyst notes on McKesson are available to download free of charge at:

http://www.analystsreview.com/Jun-20-2014/MCK/report.pdf

AbbVie Inc. Analyst Notes
On June 17, 2014, AbbVie Inc. (AbbVie) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The EMA had granted accelerated assessment status to the applications in May, while the validation of the MAAs confirms that the submissions are complete and starts the EMA's centralized review process. Once approved, AbbVie stated that the regimen could be available for marketing in Q1 2015 in the European Union (EU). The full analyst notes on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Jun-20-2014/ABBV/report.pdf

Eli Lilly and Company Analyst Notes
On June 17, 2014, Eli Lilly and Company (Lilly), together with Boehringer Ingelheim, reported the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA). According to Lilly, the Class 1 resubmission follows a complete response letter issued by the FDA that referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin - an investigational SGLT2 inhibitor being studied for the reduction of blood glucose levels in adults with diabetes - will be manufactured. The full analyst notes on Lilly are available to download free of charge at:

http://www.analystsreview.com/Jun-20-2014/LLY/report.pdf

Zoetis Inc. Analyst Notes
On June 17, 2014, Zoetis Inc. (Zoetis) announced that the Public Relations Society of America (PRSA) has recognized the Company and its agency partner Ketchum Public Relations with two awards at the 2014 Silver Anvil Awards Ceremony in New York City on June 12, 2014 - Best Investors Relations Campaign and Best Global Communications Campaign. The PRSA honored the Zoetis -Ketchum team creativity and execution of the communications activities in line with Zoetis' Independent Public Offering (IPO) on February 1, 2013. The Silver Anvil is industry's distinguished honor recognizing the leadership in Public Relations. The full analyst notes on Zoetis are available to download free of charge at:

http://www.analystsreview.com/Jun-20-2014/ZTS/report.pdf

Salix Pharmaceuticals, Ltd. Analyst Notes
On June 17, 2014, stock of Salix Pharmaceuticals, Ltd. (Salix) increased 2.85% to close at $114.84 per share. Over the previous five-day trading session, Salix's stock gained 2.48% compared to the Nasdaq Composite which decreased marginally by 0.02% during the same period. The full analyst notes on Salix are available to download free of charge at:

http://www.analystsreview.com/Jun-20-2014/SLXP/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com

SOURCE Analysts Review